Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Hong Xu1, Sara Garcia-Ptacek2, Linus Jönsson2
1From the Division of Clinical Geriatrics (H.X., S.G.-P., M.E.), Division of Neurogeriatrics (L.J., A.W.), Department of Neurobiology, Care Sciences and Society, and Department of Medical Epidemiology and Biostatistics (H.X.), Karolinska Institutet; Department of Internal Medicine (S.G.-P.), Neurology Section, Södersjukhuset, Stockholm, Sweden; H. Lundbeck A/S (L.J.), Copenhagen, Denmark; Department of Community Medicine and Rehabilitation (P.N.), Geriatric Medicine, Umeå University; and Theme Aging (S.G.-P., M.A.), Karolinska University Hospital, Stockholm, Sweden. hong.xu.2@ki.se.
Insights
Cholinesterase inhibitors (ChEIs) slow cognitive decline and reduce mortality in Alzheimer dementia patients. Galantamine specifically lowers the risk of severe dementia.
Area of Science:
- Neurology
- Pharmacology
- Geriatrics
Background:
- Alzheimer dementia is characterized by progressive cognitive decline.
- Cholinesterase inhibitors (ChEIs) are a class of drugs used to manage Alzheimer dementia symptoms.
- The long-term effects of ChEIs on cognitive trajectory and mortality in Alzheimer dementia are of significant clinical interest.
Purpose of the Study:
- To investigate the association between cholinesterase inhibitor (ChEI) use and the rate of cognitive decline in patients with Alzheimer dementia.
- To determine if ChEI treatment reduces the risk of severe dementia or death in this population.
Main Methods:
- A propensity score-matched cohort study was conducted using data from the Swedish Dementia Registry.
- Patients with Alzheimer dementia initiating ChEIs within 3 months of diagnosis were compared to untreated patients.
- Cognitive trajectories were assessed using Mini-Mental State Examination (MMSE) scores, and severe dementia or death was analyzed using Cox proportional hazards models.
Main Results:
- The study included 11,652 ChEI users and 5,826 nonusers over an average follow-up of 5 years.
- ChEI use was associated with a slower rate of cognitive decline (0.13 MMSE points/year) and a 27% lower risk of death.
- Galantamine showed the strongest cognitive benefit and was the only ChEI associated with a significant reduction in the risk of severe dementia.
Conclusions:
- Cholinesterase inhibitors offer modest but persistent cognitive benefits and reduce mortality risk in Alzheimer dementia patients.
- The observed cognitive effects may partially explain the reduced mortality associated with ChEI use.
- Galantamine demonstrated a unique ability to significantly decrease the risk of developing severe dementia.
Objective:
To investigate whether cholinesterase inhibitors (ChEIs) are associated with slower cognitive decline in Alzheimer dementia and decreased risk of severe dementia or death.
Methods:
Patients with Alzheimer dementia from the Swedish Dementia Registry starting on ChEIs within 3 months of the dementia diagnosis were included and compared to nontreated patients with Alzheimer dementia. In a propensity score-matched cohort, the association between ChEI use and cognitive trajectories assessed by Mini-Mental State Examination (MMSE) scores was examined with a mixed model, and severe dementia (MMSE score <10) or death as an outcome was assessed with Cox proportional hazards models.
Results:
The matched cohort included 11,652 ChEI users and 5,826 nonusers. During an average of 5 years of follow-up, 255 cases developed severe dementia, and 6,055 (35%) died. ChEI use was associated with higher MMSE score at each visit (0.13 MMSE points per year; 95% confidence interval [CI] 0.06-0.20). ChEI users had a 27% lower risk of death (0.73, 95% CI 0.69-0.77) compared with nonusers. Galantamine was associated with lower risk of death (0.71, 95% CI 0.65-0.76) and lower risk of severe dementia (0.69, 95% CI 0.47-1.00) and had the strongest effect on cognitive decline of all the ChEIs (0.18 MMSE points per year, 95% CI 0.07-0.28).
Conclusions:
ChEIs are associated with cognitive benefits that are modest but persist over time and with reduced mortality risk, which could be explained partly by their cognitive effects. Galantamine was the only ChEI demonstrating a significant reduction in the risk of developing severe dementia.
Classification Of Evidence:
This study provides Class III evidence that for patients with Alzheimer dementia ChEIs decrease long-term cognitive decline and risk of death and that galantamine decreases the risk of severe dementia.
More Related Videos
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:22Alzheimer's Disease: Treatment
01:26Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...